Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EPS (Basic): 2022-2025

Historic EPS (Basic) for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$0.52.

  • ARS Pharmaceuticals' EPS (Basic) fell 160.00% to -$0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.82, marking a year-over-year decrease of 60.78%. This contributed to the annual value of $0.08 for FY2024, which is 114.04% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported EPS (Basic) of -$0.52 as of Q3 2025, which was down 13.04% from -$0.46 recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' EPS (Basic) peaked at $0.51 during Q4 2024, and registered a low of -$0.52 during Q3 2025.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.16 (2023), whereas its average is -$0.17.
  • In the last 5 years, ARS Pharmaceuticals' EPS (Basic) surged by 828.57% in 2024 and then slumped by 253.85% in 2025.
  • Quarterly analysis of 4 years shows ARS Pharmaceuticals' EPS (Basic) stood at -$0.43 in 2022, then surged by 83.66% to -$0.07 in 2023, then spiked by 828.57% to $0.51 in 2024, then crashed by 160.00% to -$0.52 in 2025.
  • Its EPS (Basic) was -$0.52 in Q3 2025, compared to -$0.46 in Q2 2025 and -$0.35 in Q1 2025.